➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
McKinsey
Baxter
Merck
McKesson

Last Updated: April 12, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BRODALUMAB

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for brodalumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01708590 Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects Terminated Amgen Phase 3 2012-08-01 The purpose of this study is to assess the safety and efficacy of brodalumab taken every two weeks at two different doses in participants with moderate to severe plaque psoriasis. A second purpose of this study is to assess the safety and efficacy when brodalumab is replaced with placebo in some participants compared with the participants who are still receiving the brodalumab.
NCT01708603 Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects Terminated Amgen Phase 3 2012-08-01 The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis. A second purpose of this study is to assess the safety and efficacy brodalumab at two different doses compared with ustekinumab in participants with moderate to severe plaque psoriasis. A third purpose of this study is to assess the safety and efficacy of 4 maintenance regimens of brodalumab.
NCT01708629 Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects Terminated Amgen Phase 3 2012-09-01 The purpose of this study is to assess the safety and efficacy of brodalumab at two different doses compared with placebo in participants with moderate to severe plaque psoriasis. A second purpose of this study is to assess the safety and efficacy brodalumab at two different doses compared with ustekinumab in participants with moderate to severe plaque psoriasis. A third purpose of this study is to assess the safety and efficacy of 4 maintenance regimens of brodalumab.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for brodalumab

Condition Name

Condition Name for brodalumab
Intervention Trials
Psoriasis 6
Moderate to Severe Plaque Psoriasis 5
Hidradenitis Suppurativa 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for brodalumab
Intervention Trials
Psoriasis 13
Hidradenitis 3
Arthritis, Psoriatic 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for brodalumab

Trials by Country

Trials by Country for brodalumab
Location Trials
United States 132
Canada 30
Spain 14
Australia 11
Mexico 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for brodalumab
Location Trials
Texas 8
New York 8
Florida 7
California 7
Arizona 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for brodalumab

Clinical Trial Phase

Clinical Trial Phase for brodalumab
Clinical Trial Phase Trials
Phase 4 7
Phase 3 8
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for brodalumab
Clinical Trial Phase Trials
Not yet recruiting 9
Terminated 4
Completed 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for brodalumab

Sponsor Name

Sponsor Name for brodalumab
Sponsor Trials
Amgen 8
LEO Pharma 3
Kyowa Kirin Co., Ltd. 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for brodalumab
Sponsor Trials
Industry 19
Other 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Dow
Harvard Business School
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.